Bilaketaren emaitzak - Alberto D’Angelo

  • Erakusten 1 - 11 emaitzak -- 11
Findu emaitzak
  1. 1
    Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma

    Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma nork Navid Sobhani, Matteo Pittacolo, Alberto D’Angelo, Giovanni Marchegiani

    Argitaratua 2025
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer

    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer nork Navid Sobhani, Alberto D’Angelo, Matteo Pittacolo, Giandomenico Roviello, Tobias Otto

    Argitaratua 2019
    Testu osoa
    Pré-impressão
    Gogokoenen artean sartu
    Gorde:
  3. 3
    MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy

    MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy nork Maria Grazia Rodriquenz, Giandomenico Roviello, Alberto D’Angelo, Daniele Lavacchi, Franco Roviello, Karol Połom

    Argitaratua 2020
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Advances in anti-BRAF therapies for lung cancer

    Advances in anti-BRAF therapies for lung cancer nork Giandomenico Roviello, Alberto D’Angelo, Marianna Sirico, Matteo Pittacolo, Felipe Umpierre Conter, Navid Sobhani

    Argitaratua 2021
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy

    Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy nork Marianna Sirico, Alberto D’Angelo, Caterina Gianni, Chiara Casadei, Filippo Merloni, Ugo De Giorgi

    Argitaratua 2023
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

    Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer nork Giandomenico Roviello, Alberto D’Angelo, Roberto Petrioli, Franco Roviello, Fabio Cianchi, Stefania Nobili, Enrico Mini, Daniele Lavacchi

    Argitaratua 2020
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  7. 7
    AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption

    AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption nork Navid Sobhani, Praveen Neeli, Alberto D’Angelo, Matteo Pittacolo, Marianna Sirico, Ilaria Camilla Galli, Giandomenico Roviello, Gabriella Nesi

    Argitaratua 2021
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer

    Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer nork Navid Sobhani, Anna Ianza, Alberto D’Angelo, Giandomenico Roviello, Fabiola Giudici, Marina Bortul, Fabrizio Zanconati, Cristina Bottin, Daniele Generali

    Argitaratua 2018
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer

    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer nork Navid Sobhani, Alberto D’Angelo, Matteo Pittacolo, Giandomenico Roviello, Anna Miccoli, Silvia Paola Corona, Ottavia Bernocchi, Daniele Generali, Tobias Otto

    Argitaratua 2019
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Methylene Blue—Current Knowledge, Fluorescent Properties, and Its Future Use

    Methylene Blue—Current Knowledge, Fluorescent Properties, and Its Future Use nork Tomasz Cwalinski, Wojciech Połom, Luigi Marano, Giandomenico Roviello, Alberto D’Angelo, Natalia Cwalina, Marcin Matuszewski, Giandomenico Roviello, Janusz Jaśkiewicz, Karol Połom

    Argitaratua 2020
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  11. 11
    Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies

    Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies nork Alberto D’Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello

    Argitaratua 2020
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: